Skip to main content
. Author manuscript; available in PMC: 2019 Aug 16.
Published in final edited form as: Cell Rep. 2019 Jun 25;27(13):3741–3751.e4. doi: 10.1016/j.celrep.2019.05.101

Figure 4. Chronic Levetiracetam Treatment Normalizes Neurogenesis in APP Mice.

Figure 4.

(A) After 2 weeks of treatment with saline or levetiracetam (LEV; 75 mg/kg), 2-month-old NTG and APP mice (n = 9–11 mice per genotype and treatment) were sacrificed, and the percentage of Ki67+ Nestin+ dividing NSCs was quantified. Two-way ANOVA: genotype (p < 0.01), treatment (p < 0.05). Scale bar, 100 μm.

(B) The total number of Nestin+ NSCs in NTG and APP mice treated with saline or LEV. Two-way ANOVA: genotype (p < 0.05), treatment and genotype interaction (p < 0.05). Scale bar, 100 μm.

(C) DCX expression in NTG and APP mice treated with saline or LEV. Two-way ANOVA: treatment (p < 0.0001), treatment and genotype interaction (p < 0.05). Scale bar, 100 μm.

*p < 0.05; **p < 0.01; ***p < 0.001; Holm Sidak post hoc test. Values indicate mean ± SEM. See also Figures S7 and S8 and Tables S1 and S2.